Serum Visfatin in non-obese male normal and coronary artery disease patients

Authors

  • Shaheena Naz
  • Attiqa Khalid
  • Ijlal Zehra
  • Zuniarah Hamayun
  • Maria Gill
  • Hifza Noor Lodhi

DOI:

https://doi.org/10.69656/pjp.v17i1.1185

Keywords:

Visfatine, Diabetese, Coronary Artery Disease, Obesity, Waist circumference, Hip cirference, Body Mass Index

Abstract

Background: Mechanism of direct cardioprotective action of visfatin is still unclear. The aim of this study was to detect the serum visfatin concentration in healthy males and compare it with non-obese male patients of coronary artery disease to access the cardioprotective role of visfatin. Methodology: It was a cross-sectional, comparative study. Data was collected from July to December 2018 after obtaining informed consent of the subjects. The participants included 20 non-obese healthy males, and non-obese males angiographically confirmed having coronary artery disease. All participants were non-smoker, non-diabetic, and age matched from 35–55 years. Serum visfatin was analyzed using ELISA. Anthropometric measurements including waist circumference, hip circumference, and body mass index was evaluated and correlated with serum visfatin. Statistical analysis was done using SPSS-20. The values were considered significant at p<0.05. Results: Serum visfatin levels were significantly lower (3.90 ng/ml) in non-obese coronary artery disease group as compared to healthy males (4.85 ng/ml). No significant correlation was found with anthropometric measurements. Conclusion: Significant lower level of serum visfatin in non-obese male coronary artery disease patients depicts its probable cardioprotective role that is independent of anthropometric measurements.

Pak J Physiol 2021;17(1):30–2

Downloads

Download data is not yet available.

References

Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307(5708):426–30.

Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD, et al. Pre–B cell colony–enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004;113(9):1318–27.

Lim SY, Davidson SM, Paramanathan AJ, Smith CC, Yellon DM, Hausenloy DJ. The novel adipocytokine visfatin exerts direct cardioprotective effects. J Cell Mol Med 2008;12:1395–403.

Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia–reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 2004;61(3):448–60.

Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev 2007;12(3–4):217–34.

Davidson SM, Hausenloy D, Duchen MR, Yellon DM. Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection. Int J Biochem Cell Biol 2006;38(3):414–9.

Lovren F, Pan Y, Shukla PC, Quan A, Teoh H, Szmitko PE, et al. Visfatin activates eNOS via Akt and MAP kinases and improves endothelial cell function and angiogenesis in vitro and in vivo: translational implications for atherosclerosis. Am J Physiol Endocrinol Metab 2009;296(6):E1440–9.

Segawa K, Fukuhara A, Hosogai N, Morita K, Okuno Y, Tanaka M, et al.Visfatin in adipocytes is upregulated by hypoxia through HIF1α-dependent mechanism. Biochem Biophys Res Commun 2006;349(3):875–82.

Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994;14:1431–7.

Ye SQ, Zhang LQ, Adyshev D, Usatyuk PV, Garcia AN, Lavoie TL, et al. Pre-B-cell-colony-enhancing factor is critically involved in thrombin-induced lung endothelial cell barrier dysregulation. Microvasc Res 2005;70(3):142–51.

Garcia JG, Moreno Vinasco L. Genomic insights into acute inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol 2006;291(6):L1113–7.

Ognjanovic S, Bao S, Yamamoto SY, Garibay-Tupas J, Samal B, Bryant-Greenwood GD. Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. J Mol Endocrinol 2001;26(2):107–17.

van der Veer E, Nong Z, O’Neil C, Urquhart B, Freeman D, Pickering JG. Pre-B-cell colony-enhancing factor regulates NAD+-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation. Circ Res 2005;97(1):25–34.

Rongvaux A, Shea RJ, Mulks MH, Gigot D, Urbain J, Leo O, et al. Pre‐B‐cell colony‐enhancing factor, whose expression is up‐regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol 2002;32(11):3225–34.

Kim SR, Bae SK, Choi KS, Park SY, Jun HO, Lee JY, et al. Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochem Biophys Res Commun 2007;357(1):150–6.

Dahl TB, Yndestad A, Skjelland M, Øie E, Dahl A, Michelsen A, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 2007;115(8):972–80.

Berndt J, Klöting N, Kralisch S, Kovacs P, Fasshauer M, Schön MR, et al. Plasma visfatin concentrations and fat depot–specific mRNA expression in humans. Diabetes 2005;54(10):2911–6.

Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006;91(4):1578–81.

Hausenloy DJ. Drug discovery possibilities from visfatin cardioprotection?. Curr Opin Pharmacol 2009;9(2):202–7.

Lovren F, Pan Y, Shukla PC, Quan A, Teoh H, Szmitko PE, et al. Visfatin activates eNOS via Akt and MAP kinases and improves endothelial cell function and angiogenesis in vitro and in vivo: translational implications for atherosclerosis. Am J Physiol Endocrinol Metab 2009;296(6):E1440–9.

Zahorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J, Kocełak P, Semik-Grabarczyk E, Holecki M, et al. Serum concentration of visfatin in obese women. Metabolism 2007;56(8):1131–4.

Jin H, Jiang B, Tang J, Lu W, Wang W, Zhou L, et al. Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol. Diabetes Res Clin Pract 2008;79(3):412–8.

Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006;91(1):295–9.

Rezk, M. Visfatin and cardiovascular protection. J Drug Deliv Ther 2014;4(2):154–66.

Downloads

Published

31-03-2021

How to Cite

1.
Naz S, Khalid A, Zehra I, Hamayun Z, Gill M, Lodhi HN. Serum Visfatin in non-obese male normal and coronary artery disease patients. Pak J Phsyiol [Internet]. 2021 Mar. 31 [cited 2024 Dec. 22];17(1):30-2. Available from: https://pjp.pps.org.pk/index.php/PJP/article/view/1185

Issue

Vol. 17 No. 1 (2021): Pakistan Journal of Physiology

Section

Original Article

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

Pakistan Journal of Physiology, Pak J Physiol, PJP is FREE for research and academic purposes. It can be freely downloaded and stored, printed, presented, projected, cited and quoted with full reference of, and acknowledgement to the author(s) and the PJP. The contents are published with an international CC-BY-ND-4.0 License.